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Synopsis: It appeared that the introduction of the nonavalent HPV vaccination would 
improve protection against infections and related genital dysplasia. 
 
 Present at the 20th Biennial Meeting of the European Society of Gynaecological 
Oncology (ESGO 2017); November 4–7, 2017; Vienna, Austria. 
 
Abstract 
Objective 
To test the theoretical utility of incorporating nonavalent vaccination against HPV into 
a clinical setting. 
Methods 
The present retrospective study included data from consecutive patients who 
underwent HPV-DNA testing between January 1, 1998, and December 31, 2015. 
Changes in the prevalence of different HPV types were assessed during three 
periods (T1, 1998–2003; T2, 2004–2009; and T3, 2010–2015) using XY analysis. 
Results: The study included a total of 13 665 patients. Overall, 1361, 5130, 7174 
patients were included in the T1, T2, and T3 periods, respectively. The quadrivalent 
vaccine would have potentially protected against HPV in 71.5% (973/1361), 46.5% 
(2385/5130), and 26.5% (1901/7174) of patients in T1, T2, and T3, respectively 
(P<0.001 for trend). The nonavalent vaccine could have protected against HPV in 
92.5% (1259/1361), 72.3% 3709/5130), and 58.1% (4168/7174) of patients in T1, T2, 
and T3, respectively (P<0.001 for trend). The proportion of patients with genital 
dysplasia grade 2+ who did not have infections with HPV genotypes covered by the 
quadrivalent or nonavalent vaccines increased across the three periods (P<0.001 for 
trend). For all study periods, the protection provided by the nonavalent vaccine 
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would have been superior to the quadrivalent vaccine (χ2 test P<0.001). 
Conclusion: The introduction of a nonavalent vaccine could improve protection 
against HPV infections and HPV-related genital dysplasia. 
1 INTRODUCTION 
HPV is a DNA virus associated with precancerous conditions of the lower genital 
tract. Approximately 27 000 cases of HPV-related cancers occur each year in the 
USA [1, 2]. More than 100 HPV types are known, and more than 40 types can be 
spread through sexual contact. In particular, it is estimated that HPV16 and HPV18 
are the most common HPV types involved in the genesis of genital cancers, being 
involved in more than 70% of cervical cancer [1, 2]. 
 
HPV vaccines can prevent the most common types of infections. In 2006, the US 
Food and Drug Administration (FDA) approved the use of a quadrivalent vaccine 
(4vHPV-V) against four types of HPV (6, 11, 16, 18) [3,4]. A systematic review 
focusing on the impact of the 4vHPV-V, suggested that a decline in HPV16 and 
HPV18 prevalence (approximately 75%–80%) occurred in countries with high 
vaccine uptake (such as Australia and Denmark) [5,6]. Similarly, reductions of 
approximately 45% and 85% for low-grade cytological cervical abnormalities and 
high-grade cervical lesions, respectively, have been reported [7]. However, the 
potential effects of HPV vaccination are not yet utilized [8,9]. In fact, HPV-related 
disease remains a significant cause of concerns in low- and high-income countries.  
 
Recently, the FDA licensed a nonavalent vaccine against HPV (9vHPV-V). The 
9vHPV-V adds protection against five additional high-risk HPV types (31, 33, 45, 52, 
58), in addition to the four HPV types covered by the 4vHPV-V. Growing evidence 
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supports the safety profile of the new vaccine [10–16]. Ideally, the widespread 
implementation of the 9vHPV-V will dramatically reduce the prevalence of HPV-
related conditions [17–19]. 
 
Data regarding trends in the prevalence of HPV types are still scant current evidence 
is based on non-recently published data. Here, we sought to investigate trends in 
prevalence of HPV types to test the potential utility of HPV vaccinations in women. A 
secondary aim was to identify emerging HPV types not covered by the new 9vHPV-V 
to improve awareness on potentially important HPV types. 
 
2 MATERIALS AND METHODS 
In the present retrospective study, records from consecutive women who underwent 
HPV-DNA test between January 1, 1998, and December 31, 2015, at the 
Gynecologic Oncology Unit of the National Cancer Institute of Milan, Italy. Data from 
women who underwent HPV-DNA testing owing to the presence of 
suspected/diagnosed HPV-related genital infections were included in a dedicated 
database. Exclusion criteria were: (1) aged younger than 18 years; (2) withdrawal of 
consent; (3) the presence of invasive genital cancer at diagnosis. All patients 
included gave written informed consent for the use of personal information for health 
research when undergoing HPV-DNA testing. In line with Italian law, the study did not 
need require institutional review board approval, only notification. 
 
The primary endpoint was a comparison of the potential utility of the 4vHPV-V and 
9vHPV-V by evaluating the prevalence of the different HPV types over the study 
period. A secondary endpoint measure was to identify new emerging HPV types. The 
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analysis would be only theoretical because vaccination against HPV was introduced 
in Italy in 1992 for girls aged 12 years. 
 
Over the whole study period, no specific guidelines supporting different screening 
methods were in place and treating physician opted to perform HPV testing using 
their own discretion. Demographic details, HPV type data, and treatment data for 
genital precancerous and cancerous conditions were retrospectively reviewed. All 
patients underwent colposcopy evaluations in the outpatient clinic. A dedicated team 
of gynecologic oncologists performed all gynecological and colposcopic 
examinations. High-grade genital dysplasia (2+) was defined by the presence of 
moderate/severe cervical dysplasia (cervical intraepithelial neoplasia grade 2+), 
moderate/severe vaginal dysplasia, high-grade vaginal intraepithelial neoplasia 
(histologic vaginal high-grade squamous intraepithelial lesion), and moderate/severe 
vulvar dysplasia (high-grade vulvar intraepithelial neoplasia or usual type vulvar 
intraepithelial neoplasia). 
 
HPV testing was performed using the Clinical Array Technology HPV 2 assay 
(CLART; Genomica, Madrid, Spain), which combines highly specific and sensitive 
PCR with low-density array technology. Details regarding HPV testing have been 
reported elsewhere [17]. 
 
To assess changes in the prevalence of HPV types over time, the study duration was 
stratified into three periods, denoted as T1 (1998–2003); T2 (2004–2009); and T3 
(2010–2015). These periods were chosen arbitrarily to simplify data reporting. Data 
were summarized using basic descriptive statistics and the χ2 test was used to 
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compare the prevalence of HPV serotypes between the three time periods. Trends 
were calculated using XY analysis to investigate changes in serotypes over the study 
periods. All P values were two-sided and P<0.05 was considered statistically 
significant. Statistical analyses were performed using GraphPad Prism version 6.0 
(GraphPad Software, San Diego, CA, USA) and SPSS version 20.0 (IBM, Armonk, 
NY, USA). 
 
3 RESULTS 
Over the whole study period, 13 665 patients participated in screening. The 
mean±SD age was 43.3±19.6 years. Overall, 1361 (10.0%), 5130 (37.5%), and 7174 
(52.5%) patients underwent testing in T1, T2, and T3, respectively. In the entire 
cohort, 2883 (21.1%) patients were affected by HPV-related genital dysplasia grade 
2+. Considering the whole population, infections with types HPV16 and/or HPV18 
were the two most common involved in genital infections and were diagnosed in 
2664 (19.5%) patients. Other HPV types covered by the 9vHPV-V were commonly 
detected; HPV31, 33, 45, 52, and 58 were observed in 943 (6.9%), 328 (2.4%), 208 
(1.5%), 426 (3.1%), and 601 (4.4%) patients, respectively. Considering HPV-type 
prevalence over the years, the prevalence of HPV16/18 decreased dramatically 
(P<0.001 for trend), whereas the prevalence of all other HPV types slightly increased 
(P<0.001 for trend). 
 
It was observed that the 4vHPV-V could have potentially protect against HPV 
infection in 71.5% (973/1361), 46.5% (2385/5130), and 26.5% (1901/7174) of 
patients tested in T1, T2 and T3, respectively (P<0.001 for trend; Figure 1). Further, 
administration of the 9vHPV-V could have protect against HPV infections in 92.5% 
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(1259/1361), 72.3% (3709/5130), and 58.1% (4168/7174) of patients tested in T1, T2 
and T3, respectively (P<0.001 for trend). 
 
HPV-related genital dysplasia grade 2+ was diagnosed in 2883 (21.1%) patients; of 
these patients, 200 (6.9%), 1007 (34.9%), and 1676 (58.2%) were diagnosed in T1, 
T2, and T3, respectively. Among the patients with genital dysplasia grade 2+, 
HPV16/18 were observed in 467 (16.2%) patients. The proportion of HPV16/18 
infections in patients with genital dysplasia grade 2+ decreased dramatically across 
the study periods. In particular, it occurred in 70/200 (35.0%), 204/1007 (20.3%), and 
193/1676 (11.5%) patients in T1, T2, and T3, respectively (P<0.001 for trend).  
 
The proportion of patients with genital dysplasia grade 2+, who had infections with 
HPV types not related covered by the 4vHPV-V (13.0% [26/200] in T1, 21.0% 
[211/1007] in T2, and 34.0% [570/1676] in T3) and the 9vHPV-V (3.0% [6/200] in T1, 
12.0% [121/1007] in T2, and 19.0% [318/1676] in T3) increased over time (P<0.001 
for trend; Figure 2). For all study periods, the 9vHPV-V appeared to be potentially 
superior to the 4vHPV-V in protecting against HPV infection (χ2 test P<0.001; Figure 
3). If considering HPV types not covered by the 9vHPV-V, the most common HPV 
infection among the entire cohort was HPV53 (956 [7.0%]), followed by HPV51 (536 
[3.9%]), and HPV66 (521 [3.8%]). Other HPV types had a limited prevalence 
(<2.5%). Figure 4 displays the prevalence of dysplasia related to HPV16/18 and to 
other high-risk HPV infection other than HPV16-18.  
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4 DISCUSSION 
The present study investigated trends in HPV-type prevalence and reported several 
noteworthy findings. First, it was observed that, albeit HPV16/18 represent the most 
common HPV types detected both in the whole population and in patients with 
genital dysplasia 2+, a significant decrease in the prevalence of both HPV16/18 
occurred over the study period, with a concomitant critical increase in the prevalence 
of the other high-risk HPV types. Second, as expected the 9vHPV-V demonstrated 
potentially higher coverage to high-risk HPV types than the 4vHPV-V. Third, although 
it was not possible to test any cross-protection, the proportion of HPV types not 
covered by the 4vHPV-V and 9vHPV-V was observed to increase over the study 
duration. Fourth, HPV53, 51, and 66, represented three new emerging HPV types 
that, thus, deserve further attention.  
 
Accumulating evidence focusing on the clinical efficacy of the implementation of the 
4vHPV-V, in countries with high vaccine uptake, report very high coverage against 
both the low- and high-grade cervical lesions [15, 18, 19]. In keeping with the rate 
reported in the Seattle study [18], it was observed in the present study that the 
4vHPV-V protected approximately 65% of patients. Growing data support the safety 
profile of the new 9vHPV-V although evidence on its efficacy is still lacking owing to 
the recent introduction of this new vaccination program [19–21]. Therefore, in the 
absence of a high level of evidence supporting the implementation of the 9vHPV-V, 
the present retrospective study, testing the potential effects of the 9vHPV-V, could be 
useful in assessing its potential benefits. Moreover, cross protection is a well-known 
feature in HPV vaccination programs; it has been reported that vaccine efficacy 
against genital dysplasia grade 2+ associated with the composite of 12 non-vaccine 
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HPV types (HPV31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68) ranged between 
34.2% and 56.2% [10]. Interestingly, the combined results of the Costa Rica Vaccine 
Trial [19] and the PATRICIA trial [20] suggested that the efficacy of the 4vHPV-V 
against incident HPV31, 33, and 45 was approximately 37%, 38%, and 60% after 
one, two, and three doses, respectively, suggesting that the coverage guaranteed by 
both the 4vHPV-V and 9vHPV-V would be higher than expected in the present study 
[19, 20]. The main limitations of the present investigation included the inherent 
biases related to its speculative nature. Moreover, it was not possible to identify 
patients who had received the 4vHPV-V, thereby limiting the generalization of the 
results. Conversely, the large sample size included represent the main strength of 
the present study. Moreover, the present study had the merit of reporting data 
regarding HPV-type prevalence and data regarding new emerging HPV types. 
 
In conclusion, the present study investigated trends in HPV-type prevalence, and 
compared the potential clinical utility of the 4vHPV-V and 9vHPV-V. Although it was 
not possible to test cross protection, the 9vHPV-V could be effective in protecting 
against most genital dysplasia. Further prospective studies are warranted to support 
these data and to investigate the clinical utility of vaccination programs. 
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Figure 1 Trends in type-specific HPV prevalence among the entire study population. 
Abbreviations: T1, 1998–2003; T2, 2004–2009; T3, 2010–2015. 
 
Figure 2 Trends in type-specific HPV prevalence among patients with genital 
dysplasia grade 2+. Abbreviations: T1, 1998–2003; T2, 2004–2009; T3, 2010–2015. 
 
Figure 3 Trends in potential HPV-specific vaccine coverage. Abbreviations: T1, 
1998–2003; T2, 2004–2009; T3, 2010–2015; 4v, quadrivalent vaccine; 9v, 
nonavalent vaccine. 
 
Figure 4 Prevalence of genital dysplasia grade 2+ in women with infections of HPV 
16/18 or other high-risk HPV types. 
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